Business
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. The company reported a 16.7% increase in revenue, an IFRS gross profit growth of 30.9%, a 5 percentage-point expansion to 46.0% in gross profit margin and adjusted gross profit surged by25.5% year-on-year. The strong profitable growth has been dr
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. The company reported a 16.7% increase in revenue, an IFRS gross profit growth of 30.9%, a 5 percentage-point expansion to 46.0% in gross profit margin and adjusted gross profit surged by 25.5% year-on-year. The strong profitable growth has been driven by the continued momentum across research, development and manufacturing, and enhanced operational efficiency.","length":667,"tagName":"p"},{"type":"text","content":"Pioneering the Intelligent Lab and Factory","length":42,"tagName":"p"},{"type":"text","content":"One key driver of this year's record growth is the company's rapid transformation into a digitally-native powerhouse. By integrating advanced computational modeling, predictive analytics, and ontology-driven software development, WuXi Biologics has redefined the industry standard for speed, quality, and precision.","length":323,"tagName":"p"},{"type":"text","content":"These proprietary intelligent systems have streamlined the entire biologics lifecycle, resulting in:","length":100,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Minimized Complexity: Eliminating manual bottlenecks through integrated, smart-automation workflows.","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Accelerated Timelines: Utilizing high-speed project-specific data synthesis and interpretation to shorten development cycles and bring life-saving therapies to patients faster.","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Enhanced Transparency: Providing clients with data-driven "line of sight" from initial molecule discovery through CMC and into commercial manufacturing.","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":438,"olType":false},{"type":"text","content":"Dr. Chris Chen, CEO of WuXi Biologics commented: "We are redefining the CRDMO role and value as a strategic partner powered by computational insights and agile execution—critical in today's dynamic biopharma innovation landscape. At the heart of this transformation is our unwaveri...